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Abstract This position paper of the International Osteopo-
rosis Foundation makes recommendations for vitamin D
nutrition in elderly men and women from an evidence-
based perspective.
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Introduction
Vitamin D is important for bone and muscle development,
function, and preservation. The serum 25OHD concentra-
tion is the best available clinical indicator of vitamin D
status. Until recently, optimal serum 25OHD concentration
was considered to be that level associated with maximal
parathyroid hormone (PTH) suppression. Estimates of that
threshold level have clustered around 32–50 nmol/L
(12.8–20 ng/ml) and 68–75 nmol/L (27.2–30 ng/ml),
depending upon analytical approach used [1]. In the last
decade, however, the evidence base for older men and
women has grown to include many randomized, controlled
clinical trials (RCTs) with falls and fracture endpoints.
Because the RCTs have for the most part been conducted in
men and women over the age of 60 to 65 years, our
recommendations are directed at this large and growing
older segment of the adult population. Our objective is to
use available evidence to support recommendations for
optimal vitamin D status. We approach this by examining
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the efficacy of different vitamin D doses administered and
levels of 25OHD achieved in reducing risk of falls and
fractures. In this process, it is important to consider other
factors that influence serum 25OHD levels and responses to
oral vitamin D supplementation.
Determinants of serum 25OHD levels and of the serum
25OHD response to oral vitamin D
Vitamin D intake and effective sun exposure are the major
determinants of the serum 25OHD level. Several factors
influence the increment in serum 25OHD in response to a
given dose of vitamin D3, including the starting level of
25OHD. At a dose of 2.5 μg (100 IU/d), the mean
increment ranges from 2.75 nmol/l (1.1 ng/ml) at low
starting 25OHD levels to 1.75 nmol/l (0.7 ng/ml) at higher
(near optimal) starting levels [2]. The increment in 25OHD
in response to a given dose of vitamin D also varies with
body size. It is smaller in subjects with high BMI than in
individuals with normal BMI [3, 4]. Other factors affect
25OHD levels but have no known impact on 25OHD
responses to supplemental vitamin D. Estrogen use
increases measured serum 25OHD levels by increasing
levels of vitamin D binding protein [5] but does not alter
the serum 25OHD increment achieved with supplementa-
tion. Serum 25OHD levels decline with aging, but the
serum 25OHD response to a given dose of supplemental
vitamin D3 is not affected by age [6]. Similarly, the dietary
calcium intake, within the range usually consumed, does
not affect the serum 25OHD response to vitamin D
supplementation [7]. (The latter statement should not be
confused with the observations that the calcium require-
ment may be dependent upon vitamin D status and that an
adequate calcium intake is important for bone health [8].)
Finally, serum 25OHD levels vary widely across commonly
used assays. Until this problem is addressed by widespread
use of standard reference material such as the NIST
standards [9] and participation in the DEQAS quality
control program (www.deqas.org), assay variability will
continue to complicate the process of determining the
desired 25OHD level and the impact of a given dose on
serum 25OHD levels.
Falls
Vitamin D is thought to act on myocyte vitamin D receptors
to exert its effect on muscle tissue. In prospective studies,
lower serum 25OHD levels have been associated with
decreased grip strength and appendicular muscle mass in
older men and women [10, 11] Supplementation with
vitamin D has improved lower extremity muscle perfor-
mance and reduced risk of falling in several high-quality
double blind RCTs [12]. These trials have employed doses
up to 25 μg (1,000 IU) of vitamin D per day, with and
without calcium. Supplementation in amounts of 17.5 to
25 μg/day (700–1,000 IU/day) lowered risk of falling by
20% in older individuals, independent of their calcium
intake level. In contrast, supplementation with doses of
<17.5 μg/day (<700 IU/day) had no detectable effect on
falls. From this meta-analysis of available data, it appears
that a mean serum 25OHD level of at least 60 nmol/L
(24 ng/ml) is needed for optimal fall risk reduction.
Observational studies suggest that there may be benefit to
increasing serum 25OHD levels beyond 60 nmol/L
(24 ng/ml), but higher levels (and doses) have not been
evaluated in RCTs.
Fractures
Vitamin D affects fracture risk through its effects on bone
metabolism and on risk of falling. Randomized controlled
trials indicate that supplementation with vitamin D reduces
rates of bone loss in older women [13]. The impact of
supplemental vitamin D on fracture risk has been examined
mainly in men and women age 65 and older. A recent meta-
analysis revealed that vitamin D in doses in the range of
more than 10 through 20 μg/day (>400–800 IU/day)
reduced risk of non-vertebral and hip fracture by approx-
imately 20% whereas doses up through 10 μg/day
(400 IU/day) had no evident effect [14]. Doses above
20 μg/day (800 IU/day) have not been studied. The mean
serum 25OHD level associated with reduction in non-
vertebral fracture risk was 66 nmol/L (26.4 ng/ml). Hip
fracture risk reduction was observed at a mean 25OHD
level of 74 nmol/L (29.6 ng/ml) and higher. Based on this
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and other evidence, eight of ten IOF Working Group
members felt that 75 nmol/L (30 ng/ml) is the appropriate
target level of serum 25OHD for older individuals; in
contrast, two members felt that the target should be 50 to
75 nmol/l (20 to 30 ng/ml). The estimate of 75 nmol/l
(30 ng/ml) is close to the higher cluster of 25OHD levels
associated with maximal PTH suppression [1].
Other potential benefits
Vitamin D insufficiency has been implicated as a contrib-
uting factor in a growing number of important chronic
diseases including type 2 diabetes, cardiovascular disease,
selected cancers, and autoimmune diseases as well as
infections, and also to increased mortality. RCTs are needed
before causal relationships can be determined and optimal
25OHD levels for prevention can be established. The doses
and mean serum levels needed to achieve optimal impact
on these non-classical outcomes are not clear.
Global vitamin D status
Vitamin D insufficiency, whether defined as 25OHD levels
<75 or <50 nmol/L (<30 or <20 ng/ml), is prevalent
worldwide [15]. For instance, the prevalence of levels
<75 nmol/L (<30 ng/ml) in postmenopausal women has
been reported to be approximately 50% in Thailand and
Malaysia, 75% in the USA, and 90% in Japan and South
Korea. Vitamin D deficiency, defined as a level below
25 nmol/L (10 ng/ml) is very common in the Middle East
and South Asia where mean levels range from 10 to
30 nmol/L (4 to 12 ng/ml) [15, 16]. The high prevalence of
suboptimal 25OHD levels in older men and women around
the world raises the possibility that many falls and fractures
can be prevented with vitamin D supplementation.
Vitamin D preparations
Vitamin D is available in two forms, vitamin D2 (ergo-
calciferol) and vitamin D3 (cholecalciferol). Some find that
the two forms are equally effective in raising the serum
25OHD level [17] whereas others find that vitamin D3
gives a larger increment [18]. We generally recommend that
vitamin D3 be used when available. In some parts of the
world, active metabolites are available for use in the
treatment of osteoporosis. These metabolites are not a
substitute for adequate vitamin D intake. Vitamin D is the
substrate for 25OHD and the circulating 25OHD level may
be important to support the non-renal production of 1,25-
dihydroxyvitamin D. Local production of 1,25-dihydrox-
yvitamin D appears to mediate some of the non-classical
effects of vitamin D.
Recommendations
The estimated average vitamin D requirement for older adults
to reach a serum 25OHD level of 75 nmol/L (30 ng/ml) is 20
to 25 μg/day (800 to 1,000 IU/day). Considerably higher
doses would be needed to ensure that almost all older adults
reached 75 nmol/l (30 ng/ml). Efficacy of doses higher than
20 μg/day (800 IU/day) for fractures and 25 μg/day
(1,000 IU/day) for falls however have not been evaluated in
RCTs. It is therefore premature to recommend higher intakes
for all older adults at this time.
The repletion dose will vary among individuals accord-
ing to their starting level, their BMI, their effective sun
exposure, and other unidentified factors. An intake lower
than 20 μg/day (800 IU/day) may be adequate for
individuals with regular effective sun exposure. Intake
may need to be adjusted upward to as much as 50 μg/day
(2,000 IU/day) in individuals who are obese, and in those
with osteoporosis, limited sun exposure (institutionalized,
homebound), and malabsorption, and in non-European
populations known to be at high risk for vitamin D
deficiency such as those in the Middle East and South
Asia, or immigrants from such regions living in Europe. In
these and other high-risk individuals, we recommend
measuring the serum 25OHD level. The required dose to
reach 75 nmol/L can be estimated from the measured level.
Each 2.5 μg (100 IU) of added vitamin D will increase the
serum 25OHD level by about 2.5 nmol/L (range 1.75–
2.75 nmol/L) or 1.0 ng/ml (range 0.7 to 1.1 ng/ml) [2].
Because of the variability in individual 25OHD responses
to supplemental vitamin D, however, in high-risk individ-
uals, the serum 25OHD levels should be retested after about
3 months of supplementation to confirm that the target
25OHD level has been reached.
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